IceCure Medical Ltd. (NASDAQ:ICCM) Q4 2023 Earnings Conference Call April 3, 2024 10:00 AM ET

Company Participants

Michael Polyviou - EVC Group, Investor Relations
Eyal Shamir - Chief Executive Officer
Shad Wood - VP of Sales, North American
Tlalit Bussi Tel-Tzure - VP of Business Development and Global Marketing
Ronen Tsimerman - Chief Financial Officer and Chief Operating Officer

Conference Call Participants

Kemp Dolliver - Brookline Capital Markets
Yi Che - H.C. Wainwright

Operator

Good morning and thank you for standing by. Currently, all participants are in a listen-only mode. After management's discussion, there will be a question-and-answer session. Please be advised that today's conference call is being recorded.

I would now like to turn the conference over to Michael Polyviou. Please go ahead.

Michael Polyviou

Thank you, Yoni, and welcome to IceCure Medical's conference call to review the financial results for the 12 months ended December 31, 2023 and provide an update on recent operational highlights. You may refer to the earnings press release that we issued earlier this morning.

Participating on today's call are IceCure Medical's CEO, Eyal Shamir; CFO and COO, Ronen Tsimerman; VP of Sales, North American, Shad Wood; and Tlalit Bussi Tel-Tzure, VP of Business Development and Global Marketing.

Before we begin, I will now take a moment to read a statement about forward-looking statements. This call and the question-and-answer session follows it, contains forward-looking statements within the meaning of the Safe Harbor provisions of the Private Security Litigation Reform Act of 1995 and other federal security laws. Words such as expects, anticipates, intents, plans, beliefs, seeks, estimates, and similar expressions or variations of such words are intended to identify forward-looking statements.

For example, we are using forward-looking statements in this presentation when we discuss the achievements we expect to accomplish as we continue to advance our growth strategy, our position to make significant commercial advances in key markets, pursuit of regulatory approvals in various jurisdictions, including with respect to the appeal we have filed requesting review of De Novo Classification ProSense, which earlier was granted, expansion of clinical applications release of results from our clinical results, potential market adoption and future sales of IceCure's minimally invasive cryoablation technology, advancing regulatory and commercial strategies, strategic plans, and our belief that we are in position to meet our primary goals in 2024. Because such statements deal with future events and are based on IceCure's current expectations, they're subject to various risks and uncertainties and actual results, performance or achievements of IceCure could differ materially from these described or implied by the statements during this call.